申请人:Shanghai Institute of Materia Medica,
Chinese Academy of Sciences
公开号:EP3782995A1
公开(公告)日:2021-02-24
The present invention relates to a histone acetyltransferase (HAT) inhibitor. Provided are a compound represented by general formula I, a pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereomer, an atropisomer, a racemate, a polymorph, a solvate or an isotope-labeled compound (including deuterium substitution) thereof, a preparation method therefor, a pharmaceutical composition comprising the same, and use thereof in the treatment of various HAT-related diseases or conditions.
本发明涉及一种组蛋白乙酰转移酶(HAT)抑制剂。提供了一种由通式I表示的化合物,其药学上可接受的盐,立体异构体,对映异构体,顺反异构体,对映异构体,消旋体,多晶型,溶剂合物或其同位素标记化合物(包括氘取代),以及其制备方法,包含相同的药物组成,以及在治疗各种HAT相关疾病或症状中的用途。